Stemline Therapeutics Inc. (STML)
Symbol Info
Listed Symbol STML
Name Stemline Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-3.00
Price Info
21 Day Moving Average $12.0591
21 Day EMA $11.957750
50 Day Moving Average $13.3224
50 Day EMA $12.950380
200 Day EMA $13.518740
200 Day Moving Average 12.737580
52 Week High $18.22
52 Week Low $7.82
52 Week Change $-36.480900
Alpha -0.001438
Beta 1.4015
Standard Deviation 0.155978
R2 0.095939
Periods 60
Share Information
10 Day Average Volume 640,346
20 Day Average Volume 664,675
30 Day Average Volume 725,044
50 Day Average Volume 599,696
Outstanding Shares 43,955,624
Float Shares 39,900,562
Percent Float 90.77%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 219
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 5,371,162
Institute Holdings Percent -
Institute Sold Previous 3 Months 4,073,823
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,055,062
Price Change
7 Day Price Change $-0.4400005
7 Day Percent Change -3.90%
21 Day Price Change $-1.3500004
21 Day Percent Change -11.08%
30 Day Price Change $-4.42
30 Day Percent Change -28.98%
Month To Date Price Change $-1.08
Month To Date Percent -9.07%
90 Day Price Change $-4.16
90 Day Percent Change -27.75%
Quarter To Date $-4.49
Quarter To Date Percent -29.31%
180 Day Price Change $-2.79
180 Day Percent Change -20.48%
200 Day Price Change $-0.440001
200 Day Percent Change -3.90%
Year To Date $1.330000
Year To Date Percent 14.00%
Profile
Description Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. It is developing clinical stage product candidates namely SL-401, SL-801, and SL-701. The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.
Details
Issue Type CS
Market Cap $476,039,408
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 43,955,624
CEO Ivan Bergstein
Employees 96
Last Audit UQ
Classification
CIK 0001264587
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 750 Lexington Avenue
11th Floor
New York, NY 10022
Website http://www.stemline.com
Facisimile +1 646 389-0968
Telephone +1 646 502-2311
Email investorrelations@stemline.com
Key Ratios
Profitability
EBIT Margin -512.2
EBITDA Margin -511.7
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin 193.80
Profit Margin TOT -
Income Statements
Revenue $18,055,299
Revenue Per Share $0.4108
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $430,451,401
Price To Sales 26.365631
Price To Free Cash -6.6
PE High Last 5 Years -
Price To Book 5.3
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 5.3
Financial Strength
Total Debt To Equity 0.0
Int Coverage -137,978.5
Current Ratio 4.7
Leverage Ratio 1.3
Quick Ratio 4.5
Long Term Debt To Capital 0.01
Assets
Receivables Turnover 2.3
Invoice Turnover 0.40
Assets Turnover 0.20
Management Effectiveness
Return Assets -81.59
Return On Equity -102.09
Return On Capital -101.15
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
STML
Stemline T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.